In patients with T2DM, SGLT2 inhibitors can increase glucose elimination by inhibiting the expression of SGLT2 protein and decreasing the reabsorption of glucose by the kidney, thus reducing hyperglycemia and improving the insulin secretion and peripheral insulin sensitivity [184]. Here, SLC5A2 is linked to type 2 diabetes mellitus.